2m 2m 2m 2m 2m 2m 2m
IMMUNITYBIO (IBRX)
NASDAQ
$7.37+$0.15 (+2.08%)
Price as of Jun 23, 2026 7:13 PM EDT- $7.6BMarket Cap
- 161.59%1-Year Change
- BiotechnologyIndustry
IMMUNITYBIO (IBRX)
$7.37+$0.15 (+2.08%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 113.0M +666.24% | 14.7M +2,270.58% | 622,000 +159.17% | 240,000 -74.30% | |
Cost of Revenue | 753,000 N/A | 0 N/A | N/A N/A | N/A N/A | |
Gross Profit | 112.5M +663.21% | 14.7M +2,270.58% | 622,000 +159.17% | 240,000 -74.30% | |
Sales and Marketing Expense | 147.2M -12.80% | 168.8M +30.21% | 129.6M +26.20% | 102.7M -24.06% | |
Research and Development Expense | -207.9M +9.33% | -190.1M -18.17% | -232.4M -6.36% | -248.1M +26.63% | |
Depreciation and Amortization Expense | 15.5M -11.56% | 17.6M -5.18% | 18.5M +1.38% | 18.3M +28.25% | |
Total Operating Expenses | 369.3M +2.89% | 358.9M -1.09% | 362.9M +3.22% | 351.5M +6.14% | |
Operating Profit | -256.0M -25.61% | -344.2M -4.99% | -362.3M +3.12% | -351.3M +6.36% | |
Interest Income | 6.4M -19.69% | 8.0M +605.13% | 1.1M +136.60% | -3.1M -24.63% | |
Interest Expense | -51.5M -55.05% | -114.7M -11.24% | -129.2M +103.41% | -63.5M +327.74% | |
Interest Income and Expense and Net | -45.1M -57.70% | -106.7M -16.69% | -128.1M +92.28% | -66.6M +251.50% | |
Total Nonoperating Income and Expense | -95.6M +37.60% | -69.5M -68.66% | -221.6M +235.88% | -66.0M +237.38% | |
Income before Taxes | -351.6M -15.00% | -413.6M -29.16% | -583.9M +39.93% | -417.3M +19.28% | |
Income Taxes | -135,000 N/A | 0 +100.00% | -40,000 -217.65% | 34,000 +277.78% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -351.4M -15.03% | -413.6M -29.09% | -583.2M +40.00% | -416.6M +20.12% | |
Net Income from Continuing Operations Applicable to Common | -351.6M -15.00% | -413.6M -29.16% | -583.9M +39.93% | -417.3M +19.28% | |
Basic EPS and Net Income | -0.38 -35.59% | -0.59 -48.70% | -1.15 +10.58% | -1.04 +16.85% | |
Diluted EPS and Net Income | -0.38 -38.71% | -0.62 -46.09% | -1.15 +10.58% | -1.04 +16.85% | |
Basic Weighted Average Shares | 919.9M +31.92% | 697.3M +37.09% | 508.6M +27.19% | 399.9M +2.74% | |
Diluted Weighted Average Shares | 919.9M +31.33% | 700.4M +37.71% | 508.6M +27.19% | 399.9M +2.74% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 88.3M -38.41% | 143.4M -45.97% | 265.5M +153.68% | 104.6M -42.22% | |
Short-Term Investments | 154.5M +2,321.00% | 6.4M +532.41% | 1.0M -60.32% | 2.5M -98.13% | |
Cash and Cash Equivalents and Short-Term Investments | 242.8M +62.09% | 149.8M -43.78% | 266.5M +148.60% | 107.2M -66.20% | |
Total Current Assets | 314.9M +70.58% | 184.6M -37.23% | 294.1M +109.20% | 140.6M -57.95% | |
Accumulated Depreciation | 112.5M +12.95% | 99.6M +18.03% | 84.4M +21.84% | 69.3M +30.48% | |
Property and Plant and Equipment and Net | 114.3M -16.65% | 137.1M -6.15% | 146.1M +1.69% | 143.7M +73.37% | |
Total Long-Term Assets | 4.5M -6.15% | 4.8M +67.60% | 2.9M -40.74% | 4.9M -28.27% | |
Total Assets | 501.9M +31.07% | 382.9M -24.09% | 504.5M +39.21% | 362.4M -22.72% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 1.8M N/A | N/A N/A | 0 -100.00% | 431.9M +44.33% | |
Total Current Liabilities | 61.8M +12.39% | 54.9M -5.73% | 58.3M -88.36% | 500.9M +35.74% | |
Total Long-Term Debt | 801.7M +181.89% | 284.4M -66.02% | 837.0M +246.89% | 241.3M -21.24% | |
Total Long-Term Liabilities | 424,000 -33.65% | 639,000 -42.38% | 1.1M +142.67% | 457,000 +83.53% | |
Total Liabilities | 1.0B +14.97% | 871.1M -20.11% | 1.1B +34.26% | 812.2M +13.94% | |
Retained Earnings | -3.7B +10.41% | -3.4B +13.96% | -3.0B +24.52% | -2.4B +21.23% | |
Total Stockholders Equity | -500.5M +2.32% | -489.1M -16.68% | -587.0M +31.22% | -447.3M +84.71% | |
Total Shares Outstanding | 1.0B +18.63% | 852.9M +27.13% | 670.9M +59.14% | 421.6M +5.97% | |
Cash Flow | |||||
Cash from Operating Activities | -304.9M -22.06% | -391.2M +6.67% | -366.8M +8.67% | -337.5M +22.99% | |
Capital Expenditures | 3.8M -44.16% | 6.9M -77.48% | 30.6M -60.87% | 78.2M +132.88% | |
Cash from Investing Activities | -149.8M +1,123.26% | -12.2M -59.81% | -30.5M -211.62% | 27.3M +132.16% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 400.2M +42.12% | 281.6M -49.56% | 558.3M +139.00% | 233.6M -53.78% | |
Financials Ratio | |||||
Gross Margin | 99.33% -0.67% | 100.00% N/A | N/A N/A | N/A N/A | |
Operating Margin | -226.61% -90.29% | -2,334.23% -95.99% | -58,239.55% -60.21% | -146,374.17% +313.93% | |
Return on Assets | -79.43% -14.79% | -93.21% -30.73% | -134.56% +34.26% | -100.22% -10.30% | |
Return on Equity | 71.02% -7.60% | 76.86% -31.84% | 112.77% -6.67% | 120.83% -78.26% | |
Revenue Growth | 666.24% -70.66% | 2,270.58% +1,326.54% | 159.17% +314.21% | -74.30% -110.02% | |
Current Ratio | 5.10 +51.78% | 3.36 -33.42% | 5.05 +1,697.58% | 0.28 -69.02% | |
Cash Ratio | 1.43 -45.20% | 2.61 -42.69% | 4.55 +2,080.28% | 0.21 -57.44% | |
Debt-to-Equity Ratio | -1.61 N/A | N/A N/A | -1.43 -5.26% | -1.50 -39.82% | |
Debt-to-Assets Ratio | 1.60 N/A | N/A N/A | 1.66 -10.70% | 1.86 +43.85% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow